Share This Author
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer.
The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
- B. Krause, M. Souvatzoglou, M. Schwaiger
- Medicine, BiologyEuropean Journal of Nuclear Medicine and…
The detection rate of [11C]Choline-PET/CT shows a positive relationship with serum PSA-levels in patients with biochemical recurrence of prostate cancer after primary therapy and allows not only to diagnose but also to localise recurrent disease with implications on disease management (localised vs systemic therapy).
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
A molecular imaging TNM system (miTNM, version 1.0) is proposed as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI, designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions.
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer imaging and are needed for implementation of this modality in science and routine clinical practice.
Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
- A. Buck, K. Herrmann, T. Stargardt, T. Dechow, B. Krause, J. Schreyögg
- MedicineJournal of Nuclear Medicine Technology
- 1 March 2010
The current knowledge of economic evaluations of PET and PET/CT in oncologic applications is reported on and an approach toward the implementation of these tests in future clinical studies is suggested.
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
Using blinded reads and independent lesion validation, this single-arm prospective trial establishes high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer.
The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
- Martin Barrio, J. Czernin, W. Fendler
- Medicine, BiologyThe Journal of Nuclear Medicine
- 12 January 2017
The management was changed in more than one third of patients undergoing SSTR PET/CT even when performed after an 111In-Octreotide scan, underlining the clinical impact of SSTRPET/CT.
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
Changes in tumor metabolic activity during chemotherapy predict response, prognosis, and recurrence, and provide the basis for clinical trials in which preoperative treatment is changed for patients without a metabolic response early in the course of therapy.
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
- C. Kratochwil, W. Fendler, K. Herrmann
- MedicineEuropean Journal of Nuclear Medicine and…
- 22 August 2019
The purpose of this guideline is to assist nuclear medicine specialists to deliver PSMA-RLT as an “unproven intervention in clinical practice”, in accordance with the best currently available knowledge.